Clinical TrialsThe Phase 2 data for anito-cel presents a compelling clinical profile, with a 97% overall response rate, coupled with a 62% stringent complete response/complete response rate.
Financial HealthEnding 2024 with $626M in cash, equivalents, and marketable securities, the company reiterated a financial runway into 2027, indicating strong financial health.
Product LaunchAnito-cel commercial launch in 2026, which should be smooth, given KITE/GILD's extensive manufacturing and commercial experience.